抗大肠癌相关抗原SC系列单抗的研究及其应用

为探讨大肠癌诊治的新途径,自1982年以来先后用新鲜大肠癌实体瘤细胞免疫并经细胞的杂交融合而研制出16种抗人大肠癌相关抗原的单克隆抗(体单抗),并命名为SC 系列单抗。这些杂交瘤细胞经连续多年的培养、冻存与复苏,至今仍能稳定分泌IgGl(13种)和 IgM(3种)型的单抗。     

131Ⅰ-chTNT单克隆抗体瘤体内注射治疗肺癌疗效观察

目的观察131Ⅰ-chTNT(131Ⅰ标记的肿瘤细胞核单克隆抗体)瘤体内注射治疗肺癌的疗效和毒性.方法25例肺癌患者采用131Ⅰ-chTNT注射液,每人2次,每次0.8 mCi/kg瘤体内直接注射.结果有效率48%,CR8%,PR40%.仅2例发生气胸,骨髓抑制0～Ⅱ度.结论131Ⅰ-chTNT瘤体内注射疗效高,毒副反应轻,值得进一步应用观察.     

~(131)I-chTNT单克隆抗体瘤体内注射治疗肺癌疗效观察

目的　观察131I-chTNT( 131I标记的肿瘤细胞核单克隆抗体 )瘤体内注射治疗肺癌的疗效和毒性。方法　 2 5例肺癌患者采用131I-chTNT注射液 ,每人 2次 ,每次 0 .8mCi/kg瘤体内直接注射。结果　有效率 48% ,CR :8% ,PR :40 %。仅 2例发生气胸 ,骨髓抑制0～Ⅱ度。结论　131I -chTNT瘤体内注射疗效高 ,毒副反应轻 ,值得进一步应用观察     

抗HBx单抗应用于肝癌导向治疗的实验研究

本研究应用基因工程技术制备的１７ＫＤ乙型肝炎病毒（ＨＢＶ）Ｘ蛋白（ＨＢｘＡｇ）免疫动物，成功地制备了抗－ＨＢｘ单克隆抗体，以此抗体对原发性肝癌（ＨＣＣ）组织行相应抗原检测，并同时进行乙型肝炎表面抗原（ＨＢｓＡｇ）及乙型肝炎病毒核心抗原（ＨＢｃＡｇ）的检测。在ＨＣＣ标本中，ＨＢｘＡｇ在癌内及癌周肝组织中的阳性率分别为５６％及４８％，ＨＢｓＡｇ为１６％，及７４％。ＨＢｃＡｇ仅见于癌周，阳性率仅为１８％。结果显示：ＨＢｘＡｇ在ＨＣＣ标本中的表达是ＨＢＶ标志物中最活跃的。在此基础上还进行了１３１Ｉ－ＨＢｘ单抗在荷人肝癌裸鼠体内的放射分布研究，给药后第７天瘤／血比值为１．５，瘤／肝比值为４．５，而对照组为０．４４及１．０４，表明１３１Ｉ－ＨＢｘ单抗对肝癌组织有较强的特异性亲和力，有可能成为新的载体用于肝癌的导向治疗     

^131I—chTNT单克隆抗体瘤体内注射治疗肺癌疗效观察

目的：观察^131I-chTNT(^131I标记的肿瘤标记细胞核单克隆抗体）瘤体内注射治疗肺癌的疗效和毒性。方法：25例肺癌患者采用^131I-chTNT注射液,每人2次,每次0.8mCi/kg瘤体内直接注射。结果：有效率48％,CR：8％,PR：40％。仅2例发生气胸,骨髓抑制0－Ⅱ度。结论：^131I-chTNT瘤体内注射疗效高,毒副反应轻,值得进一步应用观察。     

131I-chTNT结合外照射治疗实体瘤的实验研究

目的：比较单用^131I-chTNT与^132I-chTNT结合外照射对荷瘤肺癌动物模型肿瘤生长影响的差异。方法：人鼠嵌合抗肿瘤细胞核单抗（chTNT-3）是针对肿瘤坏死组织的新型抗体,具有广谱的抗肿瘤作用,用^131I标记单克隆抗体形成放射性螯合物。24只人肺腺癌荷瘤裸鼠分为4组,分别给予不同的治疗方案后比较肿瘤中24h放射活度比、肿瘤中放射活度比、平均累积吸收剂量以及累积吸收总量。结果：^131I-chTNT联合外照射组,24h肿瘤放射活度比、肿瘤中放射活度比、平均累积吸收剂量以及累积吸收总量较单纯^131I-chTNT组高（P〈0．05）,与对照组相比差异亦有统计学意义。结论：^131I-chTNT结合外照射治疗实体瘤,在给药前行20Gy的外照射组其肿瘤中24h放射活度比、肿瘤放射活度比、平均累积吸收剂量、累积吸收总量高,有助于提高治疗效果。     

放射性核素标记抗体导向治疗原发性肝癌的研究现状

放射性核素标记抗体导向治疗原发性肝癌的研究现状广西医科大学附属肿瘤医院（５３００２１）李志革综述吴英德审校导向治疗为手术不能切除的中、晚期肝癌提供了一种有希望的治疗模式，因此是原发性肝癌治疗中值得探索的课题。现就近年应用核素１３１Ⅰ标记抗体治疗肝癌的...     

大肠癌术前放免治疗及化疗与肿瘤坏死的相关性研究

】 ObjectiveTo study the influence of preoperative radioimmunotherapy and chemotherapy (or targeting chemotherapy) on neoplsatic cells of colorectal carcinoma (CRC). MethodsSixty-three patients were divided into five groups.Group A (16 cases) had been injected with anti-CEA monoclonal antibody,C50-¹³¹I conjugates with mitomycin C,at tumor location for preoperative radioimmunotherapy.Group B (10 cases) had been injected with ¹³¹I at tumor location before operation.Group C (7 cases) had received preoperative i.v. mitomycin for chemotherapy. Group D (13 cases) had recived preoperative i.v. targeting chemotherapy with CEA-mitomycin. Group E (17 patients) had not received any preoperative anti-tumor medication. The tumors of all patients were resected. The resected specimens were assessed by histologic examination. ResultsIn group A,there were 2 cases in 1st grade,10 cases in 2nd grade and 4 cases in 3rd grade necrosis of tumor tissue.In group B,6 cases in 1st grade, 4 cases in 2nd grade and no cases in 3rd grade necrosis.In group C,2 cases in 1st grade,5 cases in 2nd grade necrosis.In group D, 2 in 1st grade,7 in 2nd and 4 in 3rd grade necrosis.But in group E,all resected tumor tissues of 17 patients were in 1st grade necrosis. Conclusion① Preoperative radioimmunotherapy,chemotherapy (or tageting chemotherapy) and preoperative injection of radioisotope ¹³¹I could cause necrosis of tumor tissue.② It was considered to be useful using preoperative treatment to colorectal carcinoma.     

Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts

Hyperthermia (HT) may increase tumor targeting of a radiolabeled antibody by its effects on tumor vasculature and antigen expression. Expression of a 45-kDa glycoprotein antigen on LS180 colon cancer cells was 2.7-fold enhanced 2 days after heating at 43°C for 1 h. Preferential tumor accumulation of ¹²⁵I-A7 recognizing this antigen was doubled and the antitumor effect of ¹³¹I-A7 was significantly improved by HT. Hyperthermia also increased tumor uptake of an irrelevant antibody but its radioactivity was rapidly cleared. These results indicate that HT increased the initial delivery of an antibody to a tumor by its vascular effect, and radioactivity was retained in tumors by increased specific binding, resulting in a better radioimmunotherapy outcome.     

晚期胰腺癌动脉灌注化疗与癌内注射的临床应用

晚期胰腺癌２１例，采用选择性动脉置管，ＡＤＭ、ＤＤＰ、５－ＦＵ灌注化疗，术中癌内注射５－ＦＵ或纯酒精。结果完全缓解４例，部分缓解７例，胰十二指肠二步切除１例；平均生存期９．１±３．４个月。晚期胰腺癌应用动脉灌注化疗与癌内注射治疗，可望获得再手术二步切除，有助于提高生活质量和延长生存期     

干扰能瘤内注射治疗实体瘤疗效观察：附14例报告

报告１９９３年１１月～１９９４年１１月期间应用干扰能瘤内（Ａ组）及瘤外（Ｂ组）注射，治疗骨软组织恶性实体瘤及转移癌１４例。Ａ组共１２例均显效，Ｂ组２例无效。提出干扰能瘤内注射治疗恶性实体瘤效果强于其它用药方式，可用于术前、术中或配合化疗，值得推广。     

Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft

We have examined the application of (90)Y-DOTA-cPAM4, anti-MUC1 IgG, in combination with the front-line drug gemcitabine as a potential therapeutic for pancreatic cancer. Athymic nude mice bearing CaPan1 human pancreatic cancer xenografts were administered 2 mg of gemcitabine on days 0, 3, 6, 9 and 12 with concurrent (90)Y-DOTA-cPAM4 (100 microCi) provided on day 0. A second group of mice received a second cycle of treatment 5 weeks after the start of the first cycle. Control groups of mice included those that received either treatment arm alone, the combined modality treatment employing a nontargeting control antibody (hLL2, anti-B-cell lymphoma) and a final group that was left untreated. Gemcitabine administered as a single agent provided no antitumor effect. A single cycle of the combined (90)Y-DOTA-cPAM4 and gemcitabine treatment provided greater inhibition of tumor growth than was observed for any of the other treatment procedures. Tumor growth was delayed for a period of 7 weeks. Two cycles of gemcitabine with concomitant (90)Y-DOTA-cPAM4 yielded significant tumor regression and increased median survival to 21 weeks vs. 12 weeks for mice receiving a single cycle of therapy (p<0.024). Median tumor volume doubling-times were 18 weeks in mice treated with 2-cycles of therapy vs. 7 weeks in mice given only 1-cycle (p<0.001), and 3.5 weeks for the group that received 2-cycles of gemcitabine concomitant with equitoxic nontargeting (90)Y-DOTA-hLL2 (p<0.001). These data suggest that addition of (90)Y-DOTA-cPAM4 RAIT to a gemcitabine treatment regimen may provide enhanced antitumor efficacy for the treatment of pancreatic cancer.     

经皮射频联合瘤内无水酒精注射治疗肝癌

目的：总结经皮肝穿射频毁损联合瘤内无水酒精注射术治疗肝癌的效果和经验。方法：经皮射频毁损与瘤内无水酒精注射术交替治疗不宜手术切除的肝癌68例。结果：随访5－15个月,经皮射频毁损与瘤内无水酒精注射术联合治疗的31例原发性单个小肝癌（≤5cm),甲胎蛋白阳性14例,术后降至正常11例,影像学疑复发2例;9例转移性肝癌（≤5cm)仅作单纯的经皮射频治疗,治疗后1例复发;28例大肝癌（＞5cm)病人全部首先行经皮肝动脉栓塞化疗,然后再作经皮肝穿射频毁损与瘤内无水酒精注射联合治疗,其中甲胎蛋白阳性15例,术后降至正常7例,下降但未降至正常5例,无下降或上升3例;影像学随访显示病灶好转或稳定21例,病情进展7例。联合治疗副作用不大,未见严重并发症。结论：经皮射频联合瘤内无水酒精注射适合对小肝癌的治疗或经皮肝动脉栓塞化疗后大肝癌的补充治疗,两者联合治疗可望提高癌局部治疗的效果。     

胃癌单克隆抗体3H11的应用

胃癌单克隆抗体(McAb)3H11具有高阳性反应率、高选择性及高亲和力的特点.以~(131)I标记后注入荷胃癌裸鼠模型中,其瘤/肝比可达8.26±1.26,定位指数达6.08 ±1.51,ID%/g达11.00±2.62.该McAb与~(131)I偶联后可明显增强后者对肿瘤的杀伤效应及减低毒副反应.~(131)I标记的McAb 3H11静脉注入19例拟行手术的胃癌患者中,16例获阳性显像(84.2%).经胃镜引导注入癌旁粘膜下行胃癌放射免疫导向手术,判别胃壁肿瘤浸润的灵敏度、特异性及准确率分别为946%,967%及959%.判别淋巴结转移的上述指标分别为99.2%、97.7%及98.8%.     

消癌平注射液联合 NP 方案治疗晚期肺癌 56 例近期疗效观察

目的 观察消癌平注射液联合NP方案治疗晚期非小细胞肺癌的临床效果.方法 将56例晚期非小细胞肺癌随机分为两组,对照组应用 NP 方案化疗,试验组应用NP方案化疗联合消癌平注射液,2个周期后评价疗效.结果 两组患者近期疗效比较差异无统计学意义,但试验组患者治疗后生活质量、机体免疫功能明显优于对照组,毒副反应低于对照组.结论 消癌平注射液能减轻 NP 方案对机体的毒副反应,提高机体免疫力,增加患者对化疗的耐受性.     

鸦胆子油乳瘤内注射辅助化疗治疗局部晚期非小细胞肺癌疗效观察

目的 探讨鸦胆子油乳瘤内注射辅助化疗治疗不可手术切除局部晚期非小细胞肺癌(LANSCLC)的临床疗效.方法 将568例不可切除LANSCLC患者随机分为治疗组和对照组,每组284例.治疗组采取鸦胆子油乳瘤内注射辅助多西他赛+顺铂化疗方案治疗,对照组单纯采取多西他赛+顺铂方案化疗.治疗后比较分析2组患者的疗效和毒副反应.结果 治疗组和对照组总有效率分别为51.4％、41.2％,差异有统计学意义(P＜0.05);治疗组治疗后Karnofsky评分改善情况优于对照组,差异有统计学意义(P＜0.05).治疗组和对照组的毒副反应均主要为骨髓抑制、恶心呕吐和静脉炎.结论 鸦胆子油乳瘤内注射辅助多西他赛+顺铂化疗方案治疗不可切除LANSCLC可提高疗效,而不增加化疗的毒副反应.